Modified insulin-like growth factor 1 containing collagen-binding domain for nerve regeneration

Jian-an Li,1,4 Chang-fu Zhao,2 Shao-jun Li,3 Jun Zhang,1 Zhen-hua Li,1 Qiao Zhang2, Xiao-yu Yang1,5, Chun-fang Zan1,5
1 Department of Orthopedics, Second Hospital of Jilin University, Changchun, Jilin Province, China
2 Department of Orthopedics, China-Japan Union Hospital, Jilin University, Changchun, Jilin Province, China
3 Department of Orthopedics, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin Province, China

Funding: This study was supported by the National Natural Science Foundation of China, No. 81350013; a grant from the Jilin Provincial Science and Technology Plan of China, No. 20160101027JC & SC201502001; and the Graduate Innovation Fund of Jilin University in China, No. 2017031 & 2017176.

Graphical Abstract

Modified insulin-like growth factor 1 (IGF-1) containing collagen-binding domain (CBD) could be an effective neurotrophic factor for promoting nerve regeneration with a prolonged therapeutic effect.

Abstract

Insulin-like growth factor 1 (IGF-1) is a potential nutrient for nerve repair. However, it is impractical as a therapy because of its limited half-life, rapid clearance, and limited target specificity. To achieve targeted and long-lasting treatment, we investigated the addition of a binding structure by fusing a collagen-binding domain to IGF-1. After confirming its affinity for collagen, the biological activity of this construct was examined by measuring cell proliferation after transfection into PC12 and Schwann cells using a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay. Immunofluorescence staining was conducted to detect neurofilament and microtubule-associated protein 2 expression, while real time-polymerase chain reaction was utilized to determine IGF-1 receptor and nerve growth factor mRNA expression. Our results demonstrate a significant increase in collagen-binding activity of the recombinant protein compared with IGF-1. Moreover, the recombinant protein promoted proliferation of PC12 and Schwann cells, and increased the expression of neurofilament and microtubule-associated protein 2 expression, while real time-polymerase chain reaction was utilized to determine IGF-1 receptor and nerve growth factor mRNA expression. Our results demonstrate a significant increase in collagen-binding activity of the recombinant protein compared with IGF-1. Moreover, the recombinant protein promoted proliferation of PC12 and Schwann cells, and increased the expression of neurofilament and microtubule-associated protein 2. Importantly, the recombinant protein also stimulated sustained expression of IGF-1 receptor and nerve growth factor mRNA for days. These results show that the recombinant protein achieved the goal of targeting and long-lasting treatment, and thus could become a clinically used factor for promoting nerve regeneration with a prolonged therapeutic effect.

Key Words: nerve regeneration; insulin-like growth factor 1; collagen-binding domain; fusion protein; collagenase; targeted therapy; neural regeneration

Introduction

Insulin-like growth factor 1 (IGF-1), a polypeptide growth factor containing 70 amino acids, has a molecular weight of about 7.5 kDa. This factor is an anabolic peptide hormone with structural similarities to proinsulin (Holman and Baxter, 1996; Twigg and Baxter, 1998; Rosen and Pollak, 1999; Clemmons, 2006). While IGF-1 can be synthesized by most organs during fetal development, it is mainly produced by hepatocytes and the pancreas after birth (Fernandez and Torres-Alemán, 2012). The IGF-1 receptor (IGF-1R), which mediates transmembrane information transfer of IGF-1, is a transmembrane glycoprotein with a tetrameric structure formed by two α and β subunits (Ammunziati et al., 2011; Benarroch, 2012). IGF-1-specific binding to IGF-1R usually triggers two canonical pathways: PI3K/Akt and MEK/ERK (Benarroch, 2012; Hayashi et al., 2013). This factor exerts potent effects on neurogenesis and synaptogenesis, as well as neuroprotective, pro-proliferative, and anti-apoptotic actions. It also has the crucial ability to promote axon regeneration and demy-
elination (Scolnick et al., 2008; Dyer et al., 2016; Rauskolb et al., 2017). Thus, IGF-1 may be a potential therapeutic factor for peripheral nerve repair. However, in its native form, it is an impractical therapy because of its limited half-life of 8–16 hours in vivo (Laron, 1999). Thus, short half-life, rapid diffusion, and complications resulting from use of high dosages limit the widespread application of IGF-1. A previous study revealed that many tissues in the body, such as aorta and skin, contain collagens and could therefore be targets of the collagen-binding domain (CBD) (Chen et al., 2007). We hypothesized that CBD could be integrated into IGF-1 to improve its current deficiencies.

In this study, we linked IGF-1 with a CBD deduced from collagenase and expressed the fusion protein using a pET-15b expression system. To verify the biological function of the synthesized protein, we tested its collagen-binding activity and effects on cell proliferation, neural differentiation, and levels of IGF-1R-mRNA in vitro.

Table 1 DNA sequences of CBD-IGF-1 and IGF-1

| Name of the sequence | Sequence (5′→3′) |
|---------------------|-----------------|
| CBD-IGF-1           | CAT ATG ACT AAA AAG ACT CTG AGA ACC GGT GGT GGC GGC GGC CCG GAA ACC CTG TCC GCC GCG GAA CTG TTT GAT GGC CTG CAG TCT GTT TGC GGT GAT CTG GCT TTC TAC TAA AAC CCG ACC GGC GTC TTT TAT GAA CCG ACC GCC GCT TAT GGT TCT TCT GCC CTT CAG CCG CAC ACC ATT GTT GAT GAA TGT TGC TTC GTT CTT TCT GTT CAT CTG GCT CCG CAG ACC GGC ATT GTT GAT GAA TGT TGC TTC GTT CTT TCT GTT CAT CTG GCT CCG CAG AAA CCG CTT CTA TCT GCT TAA CTC GAG |
| IGF-1               | CAT ATG GGT CCG GAA ACC CTG TGC GGT GCT GAA CTG GTT GAT GCT CTG CAG TTT TAT TAT AAG AAA CCG ACC GGT TAT GGT TCT TCT GCC CTT CAG CCG CAC ACC ATT GTT GAT GAA TGT TGC TTC GTT CTT TCT GTT CAT CTG GCT CCG CAG ACC GGC ATT GTT GAT GAA TGT TGC TTC GTT CTT TCT GTT CAT CTG GCT CCG CAG AAA CCG CTT CTA TCT GCT TAA CTC GAG |

Underlined zone at the 5′ end is an NdeI site and underlined zone at the 3′ end is an XhoI site. The sequence of CBD is marked in red. The gene sequence of the CBD is deduced from human collagenase. The sequence of glycine is labeled in bold. The glycine chains can prevent CBD and IGF from affecting each other. IGF-1: insulin-like growth factor 1; CBD: collagen-binding domain.

Figure 1 Polyacrylamide gel electrophoresis and western blot assay of recombinant proteins.

(A) SDS-PAGE of soluble mixtures after purification. (B) SDS-PAGE of fusion protein after purification. The molecular weight of fusion protein is between 5 to 10 kDa. (C) Western blot assay of purified proteins. Proteins were confirmed to be CBD-IGF-1 or IGF-1 by western blot assay with an anti-IGF-1 antibody. M: Protein marker; Flow: liquid spilled from gel hole; E1–3: soluble mixtures were purified with Ni-NTA affinity chromatography at pH 6.5, 5.5, or 4.5, respectively. SDS-PAGE: Sodium dodecyl sulphate-polyacrylamide gel electrophoresis; IGF-1: insulin-like growth factor 1; CBD: collagen-binding domain.

Figure 2 Dose response curve showing binding of IGF-1 and CBD-IGF-1 to rat tail collagen.

The recombinant proteins IGF-1 and CBD-IGF-1 were added to plates containing collagen and incubated overnight. Absorbance values increased with increasing protein concentration. Absorbance at 562 nm for CBD-IGF-1 was significantly higher than that of IGF-1. Data are expressed as the mean ± SD, as analyzed by two-tailed t-test. *P < 0.05, **P < 0.01, vs. IGF-1. IGF-1: Insulin-like growth factor 1; CBD: collagen-binding domain.

Materials and Methods

Construction and expression of plasmids

DNA sequences of CBD-IGF-1 and IGF-1 were designed to generate relative proteins (Kim et al., 2015). The two DNA sequences (Table 1) were designed to include restriction endonuclease sites at both ends (underlined). In addition, the DNA sequence of CBD-IGF-1 was designed to include a CBD sequence (TKKTLRT, in red) and glycine sequence (in bold). CBD-IGF-1 DNA sequences and IGF-1 DNA sequences were ligated into a similarly digested pET-15b (+) vector and transformed into E. coli BL21 (DE3) host cells, as described previously (Jacobus and Gross, 2015). Subsequently, 100 μL of host cells carrying recombinant plasmid were plated on solid Luria-Bertani (LB) medium pre-mixed with penicillin (100 μg/mL). Transfected cells grew overnight at 37°C and then monoclonal colonies were selected and plated in 10 mL of liquid LB medium pre-mixed with penicillin. Afterwards, cells grew overnight in a shaker at 150 r/min and 37°C.

Protein purification

After overnight incubation, 1 mL of transfected cells was added to 1 L of YTA medium containing ampicillin (100 μg/mL), which was left to recover at 37°C and 150 r/min to an OD_{600}...
of 0.8–1.0. Subsequently, it was induced overnight by 1 mL of isopropyl-β-D-thiogalactopyranoside (1 M) at 28°C and 150 r/min. The mixture was pelleted by centrifugation for 30 minutes at 4°C and 4,000 × g (Heraeus Sepatech, Osterode, Germany). After removal of the supernatant, the remaining pellet was frozen at −80°C for purifying the target protein.

The remaining pellet was resuspended in lysis buffer containing 50 mM phosphate-buffered saline (PBS) and 1 mM phenylmethyl sulfonylfluoride, pH 6.5. Resuspended cells were sonicated for 20 minutes (300 W, 10 s/10 s). The cell lysate was centrifuged for 30 minutes at 4°C and 10,000 × g. The supernatant was transferred to a fresh tube for future analysis, while the pellet was washed three times with 30 mL of wash buffer (2 M urea, 50 mM PBS, pH 6.5). Following the last wash, the solution was centrifuged under the same conditions. The insoluble cell pellet was resuspended by rocking in 25 mL of dissolving buffer (8 M urea, 50 mM PBS, 5 M βME, pH 6.5) overnight at 4°C. Soluble mixtures were centrifuged at 4°C and 10,000 × g for 30 minutes. For the second round of purification, the supernatant was used for CBD-IGF-1 or IGF-1 purification with Ni-NTA affinity chromatography.

Proteins were eluted by linearly decreasing the urea concentration of the dialysate from 6 M to a final concentration of 0 M (6–0 M). The dialysate was changed every day until there was no urea.

**Western blot assay**

All samples were analyzed via immunoblot with anti-IGF-1 antibody to verify the presence of CBD-IGF-1 or IGF-1. Extracted proteins were transferred to nitrocellulose membranes, blocked, and then incubated with rabbit anti-human IGF-1 monoclonal antibody (1:1,000; Abcam, Cambridge, UK) at 4°C overnight. The following day, membranes were rocked for 1 hour at room temperature with goat anti-rabbit secondary antibodies conjugated to horseradish peroxidase (1:500; Abcam). After three washes in Tris-buffered saline (PBS) twice and then incubated for 3 days in 200 µL of DMEM Medium (DMEM) containing 10% fetal bovine serum were inoculated onto poly-L-lysine-coated 96-well plates for 4 hours. After cells adhered to plates, wells were rinsed with PBS twice and then incubated for 3 days in 200 µL of DMEM containing 10% fetal bovine serum and 15, 31, 62.5, 125, 250, 500, or 1,000 ng/mL of IGF-1 or CBD-IGF-1. Cell proliferation was evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-di-phenyl-2-H-tetrazolium bromide (MTT) assay. Briefly, 20 µL of MTT solution was added to each well and incubated for 4 hours. After centrifugation, the supernatant was removed and 150 µL of dimethyl sulfoxide was added to each well. After incubation for 10 minutes, absorbance values were measured at 570 nm with an Infinite F200 microplate reader.

**Immunofluorescence staining**

Neurofilament (NF200) and microtubule-associated protein 2 (MAP2) are important cytoskeletal proteins in neurons (Chen et al., 2017). Immunofluorescence experiments were performed to characterize NF200 and MAP2 expression. Briefly, after cells were cultured for 7 days, 20 µL of mouse anti-mouse NF200 or mouse anti-mouse MAP2 (1:200 or 1:100, respectively; Abcam) solution was added to each well and incubated overnight at 4°C. After three washes with PBS, fluorescein conjugated rabbit anti-mouse IgG (1:100; Jackson ImmunoResearch, West Grove, PA, USA) was added to each well and incubated in the dark for 1 hour at 37°C. DAPI was added to counterstain nuclei. Images were observed by confocal laser-scanning microscope (Leica, Germany).

**Real time-polymerase chain reaction (RT-PCR) for IGF-1R and nerve growth factor (NGF) mRNA expression**

RT-PCR was used to analyze mRNA levels of NGF and IGF-1R in Schwann cells at different experimental periods. Total RNA was extracted from cells using TRizol (Takara Biotechnology, Dalian, China). RT-PCR reactions were performed using a SYBR Premix Ex Taq II (Tli RNaseH Plus) (Takara Biotechnology). Primer sequences (synthesized by Sangon, Shanghai, China) for NGF, IGF-1R, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were as follows: NGF forward, 5′-GTC GTG GTG TGG AGA TA-3′, reverse, 3′-GGA GTA TGA CTT CCT CA-5′; IGF-1R forward, 5′-AAA CGC TGA CCT TGA CCT CTC-3′, reverse, 3′-CAG GTA GTC CGA AGT AGG CGG-5′; and GAPDH forward, 5′-ACC ACA GTC CAT GCC ATC AC-3′, reverse, 3′-TCC ACC CTG TTA CGG AGA TC-5′. Reactions were carried out as follows: 95°C for 30 seconds, followed by 40 cycles of 95°C for 5 seconds and 56°C for 30 seconds. Amplification was performed using a Stratagene Mx3005p (Agilent, CA, USA). Expression of GAPDH mRNA was determined as an internal control. Final results are expressed as a ratio of the mRNA of interest to that of GAPDH mRNA.

**Statistical analysis**

Data, expressed as the mean ± SD, were analyzed using IBM
SPSS statistics 21.0 (IBM, Armork, NY, USA). The statistical significance of differences was set as $P < 0.05$ and $P < 0.01$ by two-tailed t-test.

Results

Construction of CBD-IGF-1 recombinant plasmids and transfection into host cells

Upon harvesting and lysing transfected cells, the soluble mixtures were centrifuged and purified with Ni-NTA affinity chromatography. Coomassie brilliant blue-stained bands of purified proteins were observed at 5–10 kDa on the gel (Figure 1A, B). The presence of CBD-IGF-1/IGF-1 was verified by western blot assay with primary anti-human IGF-1 and secondary antibody conjugated to horseradish peroxidase. As observed in the bands of Figure 1C, expressed target proteins IGF-1 and CBD-IGF-1 were between 5–10 kDa.

Collagen-binding assay of CBD-IGF-1 and IGF-1

The binding ability of the two recombinant proteins to type I collagen is shown in Figure 2, with collagen-binding activity determined by ELISA. As shown in the binding curves, absorbance at 562 nm for CBD-IGF-1 was significantly higher than for IGF-1. This result indicates an increased amount of CBD-IGF-1 bound to type I collagen.

Effect of CBD-IGF-1 on PC12 and Schwann cell proliferation

Effects of the two proteins on cell proliferation were examined by MTT assay. Within the concentration range from 15 to 250 ng/mL, CBD-IGF-1 groups showed similar proliferation rates to the IGF-1 groups (Figure 3A, B). However, as the concentration increased, the rate of cell proliferation increased. However, at concentrations of 500 ng/mL and 1,000 ng/mL, the proliferation rate of cells cultured with CBD-IGF-1 was higher than that of IGF-1.

Effect of CBD-IGF-1 on PC12 cell morphology

PC12 cells were cultured in 96-well plates for 3 days. The morphology of PC12 cells was observed by confocal laser-scanning microscope (TCS SP5, Leica). As displayed in Figure 3C, both proteins promoted cell proliferation and axon growth, which peaked at 500 ng/mL. The cells observed began to differentiate into neurons and immunofluorescence experiments were performed to further verify cell differentiation. As exhibited in Additional Figures 1 and 2, MAP2 and NF200 were observed in cells.

CBD-IGF-1 promoted IGF-1R and NGF mRNA expression in Schwann cells

Cell proliferation is the result of signal transduction, which is stimulated by IGF-1R (Fernandez and Torres-Alemán, 2012). Levels of IGF-1R were measured by RT-PCR. Expression of IGF-1-induced IGF-1R mRNA increased rapidly and gradually decreased with time. However, IGF-1R mRNA expression induced by CBD-IGF-1 was maintained at a relatively stable level for a longer period of time. Notably, CBD-IGF-1 significantly promoted NGF mRNA expression (Figure 4).

Discussion

Neurotrophic factors play an important role in the repair of nerve injury (Zhang et al., 2000; Lee et al., 2003; Yates et al., 2004; Fernandez and Torres-Alemán, 2012; Chakr et al., 2015; He et al., 2016; Sacchetti and Lambiase, 2017; Wen et al., 2017). Among neurotrophic factors, IGF-1 is a pleiotropic factor that can promote proliferation and differentiation of neurons (Nieto-Estévez et al., 2016). However, like other growth factors, neurotrophic factors are difficult to maintain at the target site for long periods of time because of their diffusion and short half-life. Moreover, a large dose of neurotrophic factors may cause harmful consequences. To overcome these obstacles, many novel drug carriers have been developed to immobilize a drug on target cells, protein, or protein regions. Results of a previous study investigating the four segments of 116-kDa Clostridium histolyticum collagenase showed that the S3 segment was the binding domain (Matsushita et al., 1998). In a later study, the same researchers found that the CBD specifically recognized and combined with the triple-helical region of collagen’s normal conformation; notably, this binding ability could be enhanced by calcium (Matsushita et al., 2001). The CBD exhibits a broad substrate spectrum because it can combine with any tissue containing type I collagen (Toyoshima et al., 2001). Although, when fusing binding domains to growth factors, it is also important to confirm that the recombinant proteins retain their activities in addition to binding collagen (Yang et al., 2009; Egawa et al., 2011).

We hypothesized that CBD could be integrated into IGF-1 protein to improve its current deficiencies for clinical application. In the present investigation, we constructed fusion proteins containing the CBD deduced from collagenase. As shown in Figure 1, the molecular weight of the fusion protein is between 5 to 10 kDa. This is important, as reports suggest that the human immune system recognizes recombinant proteins as endotoxins or antigens when they are larger than 10 kDa (Petsch and Anspach, 2000; Kim et al., 2015). It is also worth noting that function and binding ability can be improved by adding amino acids between growth factors and binding domains (Yang et al., 2009; Egawa et al., 2011). Although CBD binds to the intertwined region of the triple helix, it cannot unwind the helix (Philominathan et al., 2012).

Purified proteins were confirmed to be CBD-IGF-1 or IGF-1 by western blot assay. IGF-1 promotes proliferation of nerve cells by binding to IGF-1R, which can activate two canonical pathways: PI3K/Akt or MAPK (Mairiet-Coello et al., 2009; Yuan et al., 2015). To determine if recombinant proteins retained their IGF-1R binding activity and acquired the ability to bind type I collagen, we analyzed IGF-1R mRNA levels and performed binding assays for CBD-IGF-1. The results confirmed the affinity of CBD-IGF-1 towards type I collagen and increased ability to bind collagen. IGF-1R mRNA levels rose rapidly in Schwann cells incubated for 4 hours, and peaked after 1 day. Importantly, levels of IGF-1R mRNA stimulated by CBD-IGF-1 decreased more slowly in the following days. After incubation with the fusion protein, there was also a dramatic increase in amounts of NGF mRNA similar to that stimulated by CBD-IGF-1.
observed for IGF-1R mRNA. These results suggest that the half-life of CBD-IGF-1 is longer than that of IGF-1.

The biological activities of fusion proteins were examined using an MTT assay. With increasing concentrations, rates of cell proliferation increased. Thus, CBD-IGF-1 exhibited similar biological activities to IGF-1 in vitro. Interestingly, at concentrations of 500 ng/mL and 1,000 ng/mL, the proliferation rate of cells cultured with CBD-IGF-1 was higher than that of IGF-1. One possible reason for this phenomenon was that cells secreting type I collagen and CBD-IGF-1 bound to type I collagen, leading to a high local concentration. Morphological observation of PC12 cells showed that CBD-IGF-1 promoted cell proliferation and axon growth. Immunofluorescence experiments conducted to verify neuronal differentiation showed increased MAP2 and NF200 in cells, indicating that the fusion protein can promote neural differentiation of PC12 cells. This result, which is similar to previous research showing potent actions of IGF-1 on axon regeneration (Fernandez and Torres-Alemán, 2012), demonstrated that the recombinant proteins retain their biological activity. Moreover, addition of the CBD promoted maintenance of a relatively high concentration of IGF-1 to promote cell proliferation.

The primary limitation of this research is the need to test the immunogenicity and biological activity of CBD-IGF-1 in vivo. As such, further in vivo studies are currently underway to determine the clinical efficacy of CBD-IGF-1.

In summary, we synthesized a fusion protein containing IGF-1 and CBD, and provided a preliminary evaluation of its effectiveness. Our results achieved the goal of a targeted and long-lived recombinant CBD-IGF-1 protein, which may
Holman SR, Baxter RC (1996) Insulin-like growth factor binding protein-3: factors affecting binary and ternary complex formation. Growth Regul 6:42-47.

Jacobus AP, Gross J (2015) Optimal cloning of PCR fragments by homologous recombination in Escherichia coli. PLoS One 10:e019221.

Kim DG, Kim EY, Kim YR, Kang IS (2015) Construction of chimeric human epidermal growth factor containing short collagen-binding domain moiety for use as a wound tissue healing agent. J Microbiol Biotechnol 25:119-126.

Laron Z (1999) Somatomedin-1 (recombinant insulin-like growth factor-1): clinical pharmacology and potential treatment of endocrine and metabolic disorders. Biodrugs 11:55-70.

Lee AC, Yu VM, Lowe JB, 3rd, Brenner MJ, Hunter DA, Mackinnon SE, Sakiyama-Elbert SE (2003) Released control of nerve growth factor enhances sciatic nerve regeneration. Exp Neurol 184:295-303.

Mairet-Coello G, Tury A, DiCicco-Bloom E (2009) Insulin-like growth factor-1 promotes G(1)/S cell cycle progression through bidirectional regulation of cyclins and cyclin-dependent kinase inhibitors via the phosphatidylinositol 3-kinase/Akt pathway in developing rat cerebral cortex. J Neurosci 29:775-788.

Matsushita O, Koide T, Kobayashi R, Nagata K, Okabe A (2001) Substrate recognition by the collagen-binding domain of Clostridium histolyticum class I collagenase. J Biol Chem 276:8761-8770.

Matsushita O, Jung CM, Minami I, Katayama S, Nishi N, Okabe A (1998) A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase. J Biol Chem 273:3643-3648.

Nieto-Estévez V, Defteralı Ç, Vicario-Abejón C (2016) IGF-I: A key growth factor that regulates neurogenesis and synaptogenesis from embryonic to adult stages of the brain. Front Neurosci 10:52.

Petsch D, Anspach FB (2000) Endotxin removal from protein solutions. J Biotechnol 76:91-119.

Philominathan ST, Koide T, Matsushita O, Sakon J (2012) Bacterial collagen-binding domain targets underwent regions of collagen. Protein Sci 21:1554-1565.

Rauskolb S, Dombert B, Sendtner M (2017) Insulin-like growth factor-1 in diabetic neuropathy and amyotrophic lateral sclerosis. Neurobiol Dis 97:103-113.

Rosen CJ, Pollak M (1999) Circulating IGF-I: New perspectives for a new century. Trends Endocrin Metab 10:136-141.

Sacchetti M, Lambiase A (2017) Neurotrophic factors and corneal nerve regeneration. Neural Regen Res 12:1220-1224.

Scolmick JA, Cui K, Duggan CD, Xuan S, Yuan XB, Esftratiadis A, Ngai J (2008) Role of IGF signaling in olfactory sensory map formation and axon guidance. Neuron 57:847-857.

Toyoshima T, Matsushita O, Minami J, Nishi N, Okabe A, Itano T (2001) Collagen-binding domain of a Clostridium histolyticum collagenase exhibits a broad substrate spectrum both in vitro and in vivo. Connect Tissue Res 42:281-290.

Twigg SM, Baxter RC (1998) Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the ac- 
id-labile subunit. J Biol Chem 273:6074-6079.

Wen SY, Li AM, Mi KQ, Wang RZ, Li H, Liu HX, Xing Y (2017) In vitro neuroprotective effects of ciliary neurotrophic factor on dorsal root ganglion neurons with glutamate-induced neurotoxicity. Neural Regen Res 12:1716-1723.

Yang Y, Zhao Y, Chen B, Han Q, Sun W, Xiao Z, Dai J (2009) Collagen-binding human epidermal growth factor promotes cellularization of collagen scaffolds. Tissue Eng Part A 15:3589-3596.

Yates JM, Smith KG, Robinson PP (2004) The effect of brain-derived neurotrophic factor on sensory and autonomic function after lingual nerve repair. Exp Neurol 190:495-505.

Yuan H, Chen R, Wu L, Chen Q, Hu A, Zhang T, Wang Z, Zhu X (2015) The regulatory mechanism of neurogenesis by IGF-1 in adult mice. Mol Neurobiol 51:512-522.

Zhang JY, Luo XG, Xian CJ, Liu ZH, Zhou XF (2000) Endogenous BDNF is required for myelination and regeneration of injured sciatic nerve in rodents. Eur J Neurosci 12:4171-4180.

Zhang R, Ruan D, Zhang C (2006) Effects of TGF-beta1 and IGF-1 on proliferation of human nucleus pulposus cells in medium with different serum concentrations. J Orthop Surg Res 1:9.
Additional Figure 1 The immunofluorescence staining of MAP2.

The concentration of IGF-1/CBD-IGF-1 was 250 ng/mL. The culture medium in the control group was consistent with IGF-1/CBD-IGF-1 group except IGF-1/CBD-IGF-1. There were MAP2 in the cells.
Additional Figure 2. The immunofluorescence staining of NF200.

The concentration of IGF-1/CBD-IGF-1 was 250 ng/mL. The culture medium in the control group was consistent with IGF-1/CBD-IGF-1 group except IGF-1/CBD-IGF-1. There were NF200 in the cells.